What’s New

The New Face of Hepatitis C

Long considered an affliction of the baby boomer generation, hepatitis C now has spiked among a surprising new population: young people. Hepatitis C infections hit

Read More

Drug Safety Data Underscores Need for Pharmacovigilance

One in every three new drugs triggers side effects discovered only after Food and Drug Administration approval, new data reveals.  And that statistic begs a

Read More

Access Issues Loom Large at Munich Workshop on Biologics and Biosimilars

By Brian Kennedy, Executive Director of the Global Alliance for Patient Access When should patients switch from one medicine to another for non-medical reasons?  How can

Read More

***PRESS RELEASE*** STATEMENT FROM ALLIANCE FOR PATIENT ACCESS ON SENATOR SANDERS’ DRUG IMPORTATION AMENDMENT

Physician organization urges lawmakers to prioritize access to safe, approved medications. WASHINGTON – The Alliance for Patient Access (AfPA) made the following statement about the amendment

Read More

How Balanced Treatment, Innovation & Better Policy Can Help Solve the Opioid Epidemic

“Doctor, make my pain go away.” I hear this plea, in one form or another, from patients on a daily basis.  Yet it presents physicians like

Read More

Clinical Trials Awareness Week Focuses on Policy, Participation

What can the federal government do to raise clinical trials awareness?  Maybe a lot, suggests one organization. May 1-5 marks Clinical Trials Awareness Week, when

Read More

***PRESS RELEASE*** Health Plans Nationwide Reject 43 percent of Claims for High Cholesterol Treatment

National health plan report card analyzes PCSK9 inhibitor claims for managed care organizations  WASHINGTON – The Institute for Patient Access released a new National Health

Read More

Health Plan Report Cards Reveal High Rejection Rate for Cholesterol Meds

Rejection is never pleasant.  But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.

Read More

***PRESS RELEASE*** Biologics Prescribers Collaborative Releases New White Paper: The State of Biosimilars Policy

White paper addresses current policy issues impacting biosimilars including naming, interchangeability, and labeling and reimbursement policies   WASHINGTON – Today the Biologics Prescribers Collaborative (BPC), a project

Read More

***MEDIA ADVISORY*** Biosimilars Policy Framework Briefing to Discuss Impact on Prescribing, Reimbursement and Use

WASHINGTON – Tomorrow, April 27, the Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, will host a congressional briefing on Capitol Hill

Read More
Back to Top